An interventional study of app-based nurse-led virtual diabetes care in Type 2 Diabetes, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.
Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 11 with no phase, and was the 9th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 55–80
Rutgers, The State University of New Jersey · Sites in United States
Ages 30–80 · Healthy volunteers
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey
Ages 40–70 · Healthy volunteers
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 54 across the 12 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This 12-month pilot tests a nurse-led, app-based intervention to improve diabetes self-management for Medicaid patients. It includes MyChart messaging to give education, phone help on problem-solving with clinicians, and using a diabetes app to track data. The study aims to enhance self-management behaviors through health technology.
Guided by the Self- and Family Management Framework, which specifies facilitators and barriers to self- management behaviors, this project tests strategies for delivering virtual diabetes care to help Medicaid patients and clinicians use health information technology to support self-management behaviors. It is a 12-month pilot nurse-led, app-based behavioral intervention consisting of three evidence-based interventions: (1) education on A1C results and goal-setting via MyChart, the Epic electronic health record's patient portal; (2) a problem-solving action plan developed collaboratively by clinicians and patients; and (3) remote monitoring via mySugr, a top- rated diabetes app, to track blood glucose and identify the need for treatment adjustments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention starts at enrollment
Behavioral: app-based nurse-led virtual diabetes care
Intervention delivery 3 months after enrollment
Behavioral: app-based nurse-led virtual diabetes care
A nurse-led, app-based behavioral intervention consisting of (1) education via MyChart messaging, (2) problem solving with an action plan via phone, and (3) remote patient monitoring via mySugr app to identify the need to adjust treatment
Glycemic control: glycated hemoglobin AIC
Electronic health record extracted lab test drawn at baseline, 3, 6, 9, and 12 months
Time frame: baseline, 3, 6, 9, and 12 months
Glycemic control - the rate of pre-prandial blood glucose readings in target range
Home monitoring glucometer at baseline and diabetes app report containing blood glucose readings at home for 3, 6, 9, and 12 months. It is calculated from the number of BG that met the target divided by the total number of BG tested.
Time frame: baseline, 3, 6, 9, and 12 months
Glycemic control - the rate of peak postprandial blood glucose reading in target range
Blood glucose reading obtained from patient's home monitoring glucometer at baseline and diabetes app report containing blood glucose readings at home for 3, 6, 9, and 12 months. It is calculated from the number of BG that met the target divided by the total number of BG tested.
Time frame: baseline, 3, 6, 9, and 12 months
Diabetes Knowledge Test 2 (23 iems) for knowledge change
This scale assesses the knowledge of individuals regarding diabetes management and self-care. 0 is minimal and 23 is maximal. Higher is better outcome reflecting high knowledge.
Time frame: baseline, 3, 6, 9, and 12 months
Diabetes Empowerment Scale Short 28 items for self-efficacy change
The DES-28 has been validated and is considered a reliable tool for assessing the psychosocial aspects of diabetes management, making it useful for various educational and psychosocial interventions related to diabetes. 28 is minimal, 140 is max. Higher is better outcome, reflecting greater empowerment and self-efficacy in managing diabetes.
Time frame: baseline, 3, 6, 9, and 12 months
AHC Health-Related Social Needs Screening Tool (10 items) for Social Determinants of Health Change
It help healthcare providers identifies the social needs of their patients, which can inform interventions and resource allocation. 0 is minimal, 10 is max. Higher score is greater number of identified health-related social needs, which may suggest worse outcomes in terms of social determinants of health.
Time frame: baseline, 3, 6, 9, and 12 months
Brief Cope Inventory (28 items) for effective and ineffective ways to cope with stressful life events.
The Brief Coping Inventory is a 28-item measure that assesses 14 distinct coping strategies, with two items representing each strategy. It provides insight into how individuals manage challenges related to diabetes and general life stressors. Each item is rated on a 4-point scale ranging from 1 ("not at all") to 4 ("a lot"). Scores for each coping strategy range from 2 to 8, with higher scores indicating greater use of that specific coping style. The total score for the full inventory ranges from 28 to 112, with higher overall scores reflecting a greater reliance on coping strategies across domains.
Time frame: baseline, 3, 6, 9, and 12 months
Diabetes Distress Scale (17 items) for quality of life change
Measures emotional distress related to managing diabetes, with scores for each item ranging from 1 ("not a problem") to 6 ("a very serious problem"). It is a valuable tool for identifying patients who may need additional support in managing the emotional burdens associated with diabetes. 17 is minimal, 102 is max. Higher scores indicate greater diabetes-related distress, which is generally considered worse for overall well-being and diabetes management. Scores are typically categorized as little/no distress, moderate distress, or high distress to guide interventions.
Time frame: baseline, 3, 6, 9, and 12 months
Summary of Diabetes Self-Care Activities Measure (11 items) for Self-management activity changes
It is a reliable and valid tool for evaluating diabetes self-management behaviors and is useful in both research and clinical settings. 0 is minimal indicating no self-care activities performed, 11 is max indicating all self-care activities performed. Higher score indicate Measure consists of 11 items that assess various aspects of diabetes self-management.
Time frame: baseline, 3, 6, 9, and 12 months
Blood Glucose (BG) testing frequency change
The number of blood glucose readings obtained from patient's home monitoring glucometer at baseline and the number of blood glucose readings listed in the diabetes app report at home for 3, 6, 9, and 12 months.
Time frame: baseline, 3, 6, 9, and 12 months
Diabetes Numeracy Test short (15 items) for knowledge change
This test assesses diabetes-related numeracy skills that are essential for effective self-management of diabetes, such as interpreting blood glucose readings and calculating carbohydrate intake. 0-15, 0 is minimal with no correct answer, 15 is max. Higher is better outcome reflecting higher numeracy.
Time frame: baseline, 3, 6, 9, and 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — IPD will not be shared. Each participant will be given a unique study identification number that will be used on all study forms and data files. Each participant's identifying data will be separated from the study data. All data will be de-identified with a participant code number. The code linking a participant to their code number will be maintained in a separate file on a secure server at Rutgers (e.g., Microsoft Teams, Box).
Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 32 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →